Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Articles published by Axsome Therapeutics, Inc.

< Previous 1 2 Next >
Axsome Therapeutics Reports Third Quarter 2024 Financial Results and Provides Business Update
From Axsome Therapeutics, Inc.
Via GlobeNewswire
Tickers AXSM
Axsome Therapeutics Presents Data from Its Leading Neuroscience Pipeline at NEI Congress 2024
From Axsome Therapeutics, Inc.
Via GlobeNewswire
Tickers AXSM
Axsome Therapeutics Presents Data from Multiple Programs Spanning Its Innovative Neuroscience Portfolio at Psych Congress 2024
From Axsome Therapeutics, Inc.
Via GlobeNewswire
Tickers AXSM
Axsome Therapeutics to Report Third Quarter 2024 Financial Results on November 12
From Axsome Therapeutics, Inc.
Via GlobeNewswire
Tickers AXSM
Axsome Therapeutics Presents Data from Multiple Programs at Sleep Europe 2024
From Axsome Therapeutics, Inc.
Via GlobeNewswire
Tickers AXSM
Axsome Therapeutics Announces FDA Acceptance of NDA Resubmission for AXS-07 for the Acute Treatment of Migraine
From Axsome Therapeutics, Inc.
Via GlobeNewswire
Tickers AXSM
Axsome Therapeutics to Participate in Investor Conferences in September
From Axsome Therapeutics, Inc.
Via GlobeNewswire
Tickers AXSM
Axsome Therapeutics Reaches Agreement to Dismiss Sunosi® (Solriamfetol) Patent Litigation with Sandoz Inc.
From Axsome Therapeutics, Inc.
Via GlobeNewswire
Tickers AXSM
Axsome Therapeutics Reports Second Quarter 2024 Financial Results and Provides Business Update
From Axsome Therapeutics, Inc.
Via GlobeNewswire
Tickers AXSM
Axsome Therapeutics to Report Second Quarter 2024 Financial Results on August 5
From Axsome Therapeutics, Inc.
Via GlobeNewswire
Tickers AXSM
Axsome Therapeutics Settles Sunosi® (solriamfetol) Patent Litigation with Unichem Laboratories
From Axsome Therapeutics, Inc.
Via GlobeNewswire
Tickers AXSM
Axsome Therapeutics Joins the American Migraine Foundation to Highlight Unmet Treatment Needs During Migraine & Headache Awareness Month
From Axsome Therapeutics, Inc.
Via GlobeNewswire
Tickers AXSM
Axsome Therapeutics Supports Alzheimer’s & Brain Awareness Month
From Axsome Therapeutics, Inc.
Via GlobeNewswire
Tickers AXSM
Axsome Therapeutics to Participate in Upcoming Investor Conferences
From Axsome Therapeutics, Inc.
Via GlobeNewswire
Tickers AXSM
Axsome Therapeutics Highlights Data on Solriamfetol Demonstrating Improvement in Cognitive Function in Patients with Obstructive Sleep Apnea or Narcolepsy at SLEEP 2024
From Axsome Therapeutics, Inc.
Via GlobeNewswire
Tickers AXSM
Axsome Therapeutics Presents Data from Multiple Programs at the 2024 American Society of Clinical Psychopharmacology Annual (ASCP) Meeting
From Axsome Therapeutics, Inc.
Via GlobeNewswire
Tickers AXSM
Axsome Therapeutics to Present at Upcoming Investor Conferences
From Axsome Therapeutics, Inc.
Via GlobeNewswire
Tickers AXSM
Axsome Therapeutics Reports First Quarter 2024 Financial Results and Provides Business Update
From Axsome Therapeutics, Inc.
Via GlobeNewswire
Tickers AXSM
Axsome Therapeutics Recognizes May as Mental Health Awareness Month
From Axsome Therapeutics, Inc.
Via GlobeNewswire
Tickers AXSM
Axsome Therapeutics Highlights Innovative Neuroscience Portfolio at the American Academy of Neurology (AAN) 2024 Annual Meeting
From Axsome Therapeutics, Inc.
Via GlobeNewswire
Tickers AXSM
Axsome Therapeutics to Report First Quarter 2024 Financial Results on May 6
From Axsome Therapeutics, Inc.
Via GlobeNewswire
Tickers AXSM
Axsome Therapeutics Initiates ENGAGE Phase 3 Trial of Solriamfetol for the Treatment of Binge Eating Disorder
From Axsome Therapeutics, Inc.
Via GlobeNewswire
Tickers AXSM
Axsome Therapeutics Announces Results of CRESCENDO Narcolepsy Patient Survey Demonstrating Unmet Needs in Treated Narcolepsy Type 1 Patients
From Axsome Therapeutics, Inc.
Via GlobeNewswire
Tickers AXSM
Axsome Therapeutics Announces AXS-12 Achieves Primary Endpoint in the SYMPHONY Phase 3 Trial in Narcolepsy
From Axsome Therapeutics, Inc.
Via GlobeNewswire
Tickers AXSM
Axsome Therapeutics Initiates PARADIGM Phase 3 Trial of Solriamfetol for the Treatment of Major Depressive Disorder
From Axsome Therapeutics, Inc.
Via GlobeNewswire
Tickers AXSM
Axsome Therapeutics to Present at the Leerink Partners Global Biopharma Conference
From Axsome Therapeutics, Inc.
Via GlobeNewswire
Tickers AXSM
Axsome Therapeutics to Present at the TD Cowen 44th Annual Healthcare Conference
From Axsome Therapeutics, Inc.
Via GlobeNewswire
Tickers AXSM
Axsome Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Update
From Axsome Therapeutics, Inc.
Via GlobeNewswire
Tickers AXSM
Axsome Therapeutics to Report Fourth Quarter and Full Year 2023 Financial Results on February 20
From Axsome Therapeutics, Inc.
Via GlobeNewswire
Tickers AXSM
Axsome Therapeutics Provides Preliminary Fourth Quarter and Full Year 2023 Net Revenue and 2024 Anticipated Milestones
From Axsome Therapeutics, Inc.
Via GlobeNewswire
Tickers AXSM
< Previous 1 2 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.